upper GI bleeding

in review 5 min read Updated 2026-10-28
upper GI bleeding

Resuscitate first, endoscope within 24 h. Glasgow-Blatchford ≤1 → outpatient. Restrictive transfusion (Hb <70–80 g/L; higher with cardiovascular disease). Erythromycin before endoscopy; IV PPI optional while waiting; no tranexamic acid. Treat high-risk stigmata (Forrest Ia/Ib/IIa) endoscopically → 72 h high-dose PPI → BID to day 14. Continue ASA for secondary prevention; don’t reverse warfarin or DOACs routinely. Suspected cirrhosis → treat as variceal until proven otherwise (variceal bleeding).

UGIB admission bundle
  • 2 large-bore IVs; group & screen/crossmatch; CBC, INR, urea, creatinine, LFTs, lactate
  • Glasgow-Blatchford score; ≤1 and stable → outpatient endoscopy
  • transfuse Hb <70–80 g/L (≥80 if active cardiovascular disease); not to a “normal” Hb
  • high-dose IV PPI now — don’t delay endoscopy for it
  • erythromycin 250 mg IV 20–90 min before endoscopy
  • NPO; GI consult → endoscopy within 24 h of presentation
  • cardiac ASA for secondary prevention → continue; primary prevention → stop
  • warfarin/DOAC → hold; reverse only if life-threatening → anticoagulant reversal
  • if cirrhosis or suspected varices: octreotide + ceftriaxone, see variceal bleeding
  • no tranexamic acid
  • post-endoscopy high-risk stigmata → PPI 80 mg bolus + 8 mg/h × 72 h (ACG 2021 also accepts 40 mg BID–QID)
  • ulcer → H. pylori test; repeat if negative during the bleed
  • unstable despite resuscitation → ICU, airway before endoscopy if haematemesis + ↓LOC

risk stratification and resuscitation

Glasgow-Blatchford score (GBS) — pre-endoscopy, uses urea, Hb, SBP, HR, melaena, syncope, liver disease, heart failure. GBS 0–1 → ≤1% need intervention or die → discharge with outpatient endoscopy. GBS beats AIMS65 and pre-endoscopic Rockall for this purpose; neither is recommended for safe discharge.

Transfusion — restrictive strategy lowers mortality and rebleeding (Villanueva, NEJM 2013: threshold 70 vs 90 g/L; excluded massive exsanguination and cardiovascular disease).

  • No cardiovascular disease: transfuse <80 g/L (CAG-endorsed International Consensus); ACG uses 70 g/L. Either is defensible; 80 g/L leaves margin for the equilibration lag.
  • Cardiovascular disease: higher threshold (no agreed number; ≥80 g/L).
  • Exsanguinating bleed: thresholds don’t apply — massive transfusion protocol.

Urea:creatinine ratio — raised urea out of proportion to creatinine points to an upper source (digested blood + volume depletion).

before endoscopy

  • PPI — high-dose IV PPI downstages stigmata and reduces need for endoscopic therapy; no effect on rebleeding, surgery or mortality. Reasonable while waiting, never a reason to delay the scope. Give it even if varices are suspected — the source is unknown until the scope.
  • Erythromycin 250 mg IV 20–90 min before endoscopy — prokinetic clears clot from the stomach → better views, fewer repeat scopes. Check QTc.
  • No tranexamic acid — HALT-IT (2020) (n=12 009): no mortality benefit, more venous thromboembolism and seizures.
  • Octreotide/somatostatin — no role in nonvariceal bleeding; only if varices suspected.
  • NG tube — optional; aspirate may help prognosis but doesn’t change management.

timing of endoscopy

Within 24 h of presentation for anyone admitted. Earlier is not better in stable high-risk patients: Lau, NEJM 2020 — GBS ≥12, endoscopy within 6 h vs 6–24 h, no difference in 30-day mortality or rebleeding. Haemodynamic instability despite resuscitation → urgent endoscopy once resuscitated (intubate first if airway at risk).

endoscopic findings and post-endoscopy care

Forrestlesionrebleed risk untreatedendoscopic therapy
Ia / Ibspurting / oozinghighyes
IIanon-bleeding visible vesselhighyes
IIbadherent clotintermediateirrigate to dislodge; treat underlying lesion; PPI alone acceptable
IIc / IIIflat pigmented spot / clean baselowno — discharge early, oral PPI, feed

Endoscopic therapy: thermal coagulation, clips or sclerosant; epinephrine only in combination. Haemostatic powder (TC-325) as temporising rescue.

After haemostasis of high-risk stigmata:

  • PPI: 80 mg IV bolus + 8 mg/h × 72 h, or intermittent 40 mg IV/PO BID–QID × 72 h (ACG 2021: equivalent; the International Consensus endorses only the infusion)
  • then PPI BID until day 14, then once daily for a duration set by the cause
  • stay in hospital ≥72 h — most rebleeding happens in this window
  • no routine second-look endoscopy

Rebleeding → repeat endoscopy and endoscopic therapy → if that fails, transcatheter arterial embolisation → surgery.

Ulcer → test for H. pylori and treat (peptic ulcer disease and H. pylori). A negative biopsy-based test during the bleed (PPI, blood in the stomach) → repeat later. Confirm eradication.

antithrombotics during the bleed

ASA for secondary prevention

Continue cardiac ASA through the bleed; if it was held, restart the day haemostasis is confirmed endoscopically. Stopping it raises cardiovascular events and mortality more than it lowers rebleeding. ASA for primary prevention isn’t covered by this guidance — after a GI bleed it’s generally stopped (ACG 2023 suggests stopping after diverticular bleeds).

drugduring acute GI bleed (ACG-CAG 2022)
warfarinhold; against vitamin K and FFP; PCC preferred over FFP only if reversal needed (life-threatening bleed, INR well above range, or massive transfusion undesirable)
DOACshold; against routine PCC, idarucizumab or andexanet — short half-life does the work. Consider specific reversal only if life-threatening and dose within 24 h
antiplateletagainst platelet transfusion
DAPTkeep ASA; P2Y12 inhibitor decision with cardiology (recent stent → stent thrombosis risk)

Applies to upper and lower GI bleeding. Endoscopy is not delayed for anticoagulation. Life-threatening = shock or hypotension needing pressors or surgery, Hb drop >50 g/L, or ≥5 units RBC. Reversal agents and doses → anticoagulant reversal.

Restarting anticoagulation — resume once bleeding has stopped: resumption lowers thromboembolism and mortality (ACG 2023 LGIB, strong). No trial defines the exact day; balance thrombotic indication against rebleed risk.

secondary prevention

key points

  • Cirrhosis + GI bleed → ceftriaxone and octreotide before endoscopy regardless of the presumed source (variceal bleeding).
  • Melaena with a negative upper endoscopy and colonoscopy → small-bowel source (lower GI bleeding).

Prepared 2026-10-28. Not yet verified — check every number against the sources.

Key references

+3 more sources

Suggest a correction upper GI bleeding